Abbott signs multi-billion dollar contract:
This article was originally published in Clinica
Executive Summary
Abbott and VHA have signed a seven-year, multi-billion dollar agreement for the supply of a range of Abbott's products. The deal covers electronic drug delivery systems; critical care products; intravenous solutions and equipment and the LifeShield needlestick protection system. VHA is a network of more than 1,600 healthcare organisations and their physicians.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.